Group 1 - The total number of shares as of January 31, 2025, is 2,660,056,599, with 3,835,000 treasury shares without voting rights [2] - The theoretical number of voting rights on April 30, 2025, is 3,177,421,164, while the number of exercisable voting rights is 3,175,879,316 [2] - The double voting right is granted to fully paid-up shares held in registered form for at least two years, effective from April 3, 2016 [1] Group 2 - The number of treasury shares without voting rights decreased from 3,835,000 on January 31, 2025, to 1,541,848 on April 30, 2025 [2] - The theoretical number of voting rights increased from 3,172,669,760 on January 31, 2025, to 3,177,421,164 on April 30, 2025 [2] - The number of voting rights exercisable also saw an increase from 3,169,834,760 on January 31, 2025, to 3,175,879,316 on April 30, 2025 [2]

Monthly information relating to the total number of shares and voting rights making-up the share capital Information mensuelle relative au nombre total d’actions et de droits de vote composant le capital social Article L. 233-8 II of the French Commercial code and article 223-16of the AMF General Regulation Article L. 233-8-II du Code de commerce et article 223-16 du Règlement général de l’AMF Name and address of the Company: Planisware SADénomination sociale de l’émetteur : 200 avenue de Paris92320 Châtill ...

Group 1 - TOUAX Group is a leader in operational leasing of tangible assets such as freight railcars, river barges, and containers, managing €1.2 billion in assets [4] - The company is listed on Euronext Paris and is part of the CAC® Small and CAC® Mid & Small indexes [4] - As of May 31, 2025, TOUAX has a total of 7,011,547 shares outstanding and 8,335,228 total voting rights [2]

DASSAULT AVIATION French corporation (société anonyme) with a share capital of 62,717,627.20 euros Headquarters: 9, Rond-Point des Champs-Élysées - Marcel Dassault 75008 PARIS 712 042 456 RCS Paris Information concerning the total number of voting rights and shares as per article L. 233-8 II of the French Commercial Code (Code de commerce) and article 223-16 of the General Regulations (Règlement Général) of the French Market Authority (Autorité des Marchés Financiers) DateTotal number of shares Total number ...

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024, and May 8, 2025, alleging that the company misled investors regarding its business prospects [1][2]. Group 1: Allegations Against Iovance Biotherapeutics - The complaint states that Iovance failed to disclose that new Authorized Treatment Centers (ATCs) were facing longer timelines to begin treating patients with Amtagvi [2]. - It is alleged that the company's sales team and new ATCs were ineffective in identifying and selecting patients for Amtagvi, resulting in higher patient drop-offs [2]. - These issues led to increased costs and decreased revenue, as ATCs could not keep up with the manufactured product, making the company's positive statements about its business misleading [2]. Group 2: Financial Performance - On May 8, 2025, Iovance reported a quarterly total product revenue of $49.3 million, down from $73.7 million in the previous quarter [3]. - The company revised its full fiscal year 2025 total product revenue guidance from $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [3]. - The updated forecast was attributed to recent launch dynamics of Amtagvi and the growth trajectories and treatment timelines for new ATCs [3]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by July 14, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Core Viewpoint - Johnson Fistel, PLLP has initiated an investigation into potential breaches of fiduciary duties by the board members of Blueprint Medicines Corporation in relation to its proposed sale to Sanofi [1] Group 1: Acquisition Details - Blueprint Medicines has entered into a definitive agreement with Sanofi to sell all outstanding shares for $129.00 per share in cash, along with a non-tradeable contingent value right that could yield two milestone payments of $2 and $4 for future development and regulatory achievements related to BLU-808 [2] - The transaction agreement includes a provision that restricts Blueprint's ability to solicit or accept superior proposals, imposing a significant termination fee if the board pursues a competing bid [3] Group 2: Market Analysis - A Wall Street analyst has set a price target of $167 per share for Blueprint's common stock, which is significantly higher than the agreed transaction price of $129.00 [3]

French public limited company (société anonyme)with a share capital of €1,460,429,245.00Registered office : 1973, boulevard de la Défense92000 Nanterre – France552 037 806 RCS Nanterrewww.vinci.com DISCLOSUREOF THE NUMBER OF SHARES FORMING THE CAPITALAND OF THE TOTAL NUMBER OF VOTING RIGHTSAS OF 31 MAY 2025 Total number of shares584,171,698Theoretical number of voting rights (including treasury stock)584,171,698Number of voting rights (excluding treasury stock)561,517,947 This disclosure is on VINCI web sit ...

Information on share capital and voting rights May 2025 Statement made in accordance with article L. 233-8 II of the French commercial Code and articles 221-1 2 ° f) and 223-16 of the AMF Regulations. June 2nd, 2025 Statement made by: Nexans S.A.Registered office : 4 Allée de l’Arche - 92400 CourbevoieRCS Nanterre 393 525 852Regulated market of Euronext Paris (Compartment A) DateTotal number of sharesTotal number of voting rightsTheorical (1)Exercisable (2)May 31st, 202543,753,38043,753,380<td style="width ...

Core Viewpoint - Ichor Holdings, Ltd. is under investigation for potential violations of federal securities laws and unlawful business practices following disappointing financial results in Q1 2025, which led to a significant drop in stock price [1][2]. Financial Performance - On May 5, 2025, Ichor reported its Q1 2025 financial results, missing both EPS and revenue consensus estimates [2]. - The company reported a gross margin of 12.4%, which is below the forecasted midpoint of 14.5% [2]. - Ichor attributed the margin shortfall to purchasing more external supply than anticipated, which did not translate into expected margin flow [2]. Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Ichor on behalf of stockholders who may have suffered losses [1][3]. - The investigation focuses on whether Ichor has engaged in unlawful business practices or violated federal securities laws [1].

Core Viewpoint - A class action has been filed against Canopy Growth Corporation for allegedly misleading investors regarding its cost reduction measures and financial performance during a specific period [1][2]. Allegations - The complaint alleges that Canopy Growth Corporation failed to disclose significant costs associated with the production of Claybourne pre-rolled joints and indirect costs related to Storz & Bickel vaporizer devices, which negatively impacted gross margins and overall financial results [2]. - It is claimed that the company overstated the effectiveness of its cost reduction measures while downplaying issues related to gross margins [2]. Financial Impact - On February 7, 2025, Canopy announced disappointing financial results attributed to the costs from the Claybourne product launch and increased indirect costs, leading to a 27.24% drop in share price, closing at $2.02 [3]. Class Action Participation - Shareholders may be eligible to participate in the class action against Canopy Growth Corporation, with a deadline to contact Robbins LLP by June 3, 2025, for those wishing to serve as lead plaintiff [4]. Company Background - Robbins LLP is noted for its focus on shareholder rights litigation, aiming to help shareholders recover losses and improve corporate governance since 2002 [5].